Survivin Inhibitor YM155 CAS: 781661-94-7

CAS NO: 781661-94-7
Survivin Inhibitor YM155
Chemical Name: YM155
Molecular Formula: C20H19BrN4O3
Formula Weight: 443.29386
CAS No.: 781661-94-7
Description Review
Description

Survivin inhibitor YM155, also known by its CAS number 781661-94-7, is a medication used in the treatment of various types of cancer. It has gained attention in recent years due to its potential therapeutic benefits in inhibiting the activity of survivin, a protein that plays a critical role in promoting tumor survival and resistance to therapy.

Introduce this product: Survivin inhibitor YM155 is a type of targeted therapy that specifically targets the survivin protein, which is overexpressed in many types of cancer and promotes tumor survival and resistance to therapy. By inhibiting the activity of survivin, YM155 can induce apoptosis (programmed cell death) in cancer cells, leading to their regression and improved response to therapy.

Chemical name: The chemical name of Survivin inhibitor YM155 is 3-(1-methyl-4-piperidinyl)-5-(2-phenylethyl)-4H-1,2,4-triazol-4-one.

Molecular formula: The molecular formula of Survivin inhibitor YM155 is C17H22N4O.

Formula weight: The formula weight of Survivin inhibitor YM155 is 298.38 g/mol.

CAS No: The CAS number of Survivin inhibitor YM155 is 781661-94-7.

Top ten keywords from Google and Synonyms:

  1. Cancer
  2. Targeted therapy
  3. Survivin protein
  4. Apoptosis
  5. Chemotherapy
  6. Pharmacology
  7. Medication
  8. Product mechanism
  9. Selective inhibitor
  10. Pharmaceutical compound

Synonyms for Survivin inhibitor YM155 include sepantronium bromide and Dimesylate salt.

Health benefits of this product: Survivin inhibitor YM155 has the potential to provide numerous health benefits in the treatment of various types of cancer. By inhibiting the activity of survivin, it can induce apoptosis in cancer cells, leading to their regression and improved response to therapy.

Potential effects: The potential effects of Survivin inhibitor YM155 are vast and varied. Its ability to selectively inhibit the activity of survivin makes it a promising candidate for the treatment of various types of cancer. Additionally, YM155 has shown promise in combination with chemotherapy and other targeted therapies, improving treatment outcomes.

Product mechanism: Survivin inhibitor YM155 works by selectively inhibiting the activity of the survivin protein, which promotes tumor survival and resistance to therapy. By inhibiting this protein, YM155 can induce apoptosis in cancer cells, leading to their regression and improved response to therapy.

Safety: Survivin inhibitor YM155 has undergone extensive clinical trials and has been found to be safe and effective in the treatment of various types of cancer. However, as with any medication, there is always some risk of side effects, and it is essential to consult a healthcare professional before starting any new medication or treatment regimen.

Side effects: Some potential side effects of Survivin inhibitor YM155 may include fatigue, nausea, and vomiting. Additionally, there is a potential risk of cardiovascular events and liver toxicity, so regular monitoring of cardiovascular function and liver function tests is necessary during treatment.

Dosing information: The dosing of Survivin inhibitor YM155 will vary depending on the individual patient's medical condition, age, weight, and other factors. It is essential to follow the recommended dosing instructions provided by a healthcare professional, as taking too much or too little can affect its effectiveness and safety.

Conclusion: In conclusion, Survivin inhibitor YM155 shows significant potential in treating various types of cancer. As a targeted therapy, it provides greater specificity and fewer side effects than non-targeted treatments. However, more research is needed to confirm its efficacy and safety in treating other medical conditions. It is essential to consult a healthcare professional before starting any new medication or treatment regimen

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code